NKTR

30.2007.19%
HW

Howard W. Robin

CEO, President & Director

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Therapeutics since January 15, 2007. From January 2001 to June 2001, he served as Chief Operating Officer and President of Prime Holdings & Investments Inc. Mr. Robin served as Chief Executive Officer, President and a Director of Sirna Therapeutics, Inc. a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a Director. Prior to Sirna Therapeutics, Inc. he served in a variety of functions during many years at Berlex Laboratories. From 1991 to 2001, Mr. Robin served as Corporate Vice President and General Manager of Berlex Laboratories Inc. From 1987 to 1991, he served as Vice President of Finance & Business Development and Chief Financial Officer of Berlex Laboratories Inc. From 1984 to 1987, he served as Director of Business Planning & Development at Berlex. Prior to Berlex, he served as a Senior Associate with Arthur Andersen & Company prior to joining Berlex. Mr. Robin serves as a Director of Acologix, Inc. He has been a Director of Nektar Therapeutics since February 14, 2007. He served as a Director of Bay Area Bioscience Association. He was a Senior Associate with Arthur Andersen & Co. and also serves as a director of BayBio. Previously, he served as a Director of Prime Holdings & Investments from January 2001 to June 2001. He received his B.S. in Accounting & Finance from Farleigh Dickinson University in 1974 and serves as a member of its Board of Trustees.

Positions